Kaynes Technology Stock Plunges Amid Weak Quarterly Results and Execution Concerns

Shares in Kaynes Technology took a massive hit, plunging nearly nineteen and a half percent on Thursday. That’s the fallout from JPMorgan Chase slashing the stock following some really weak numbers from the March quarter and just general worries about how they’re actually executing things.

It wasn't a sudden event. The stock had already been sliding downhill, losing over ten percent across Monday and Tuesday. But Wednesday brought a tiny flicker of hope. That was mostly because their peer, Dixon Technologies, posted results that looked better than expected. That gave Kaynes a little bump—around three percent.

The actual performance, though, tells a different story.

Look at the March figures. Revenue for Kaynes Technology clocked in at Rs 1,242 crore. That just didn’t hit the mark. The CNBC-TV18 poll had been shooting for something much higher, around Rs 1,508 crore.

EBITDA was another letdown. They posted Rs 193 crore, way below the expected Rs 243 crore. And the margin? It was 15.5 per cent. Estimates were hovering closer to 16.1 per cent. It just wasn't there.

Net profit for the quarter was significantly lower too. It landed at Rs 91.2 crore. That was a big miss against the projected Rs 172 crore. It’s a pretty stark contrast.

And this wasn’t just a quarterly hiccup. The full-year picture is equally troubling. For FY26, revenue growth was 33 per cent. That missed management’s guidance, which was set at 51 per cent growth for the entire year.

The EBITDA margin for the full year was 15.8 per cent. That was below what the company had been guiding for, which was around 17 per cent. It feels like the whole structure is under some kind of pressure.

There were bigger concerns simmering underneath the surface, tied to the cash flow. That’s where things got really messy. Kaynes Tech reported negative operating cash flow for the quarter. That figure was Rs 600 crore. This is especially interesting because management had been talking about turning cash flow positive by the end of FY26. That confidence, it seems, was shaky.

The working capital side was also showing strain. Their average cash conversion cycle widened sharply. It jumped from 84 days up to 125 days. Receivable days also ballooned, moving from 84 to 134 days. That just signals rising pressure in managing their working capital. Things are getting tighter there.

But there’s still some solid stuff on the balance sheet. Despite the poor quarterly results, the order book remains robust. At the end of FY26, they still had Rs 8,366.3 crore in orders. That’s up from Rs 6,596.9 crore a year ago. And net debt actually shrank a bit, coming down to Rs 207.4 crore from Rs 581.3 crore previously. That’s a small positive, maybe, but it doesn't erase the operational mess.

JPMorgan didn't hold back. They downgraded the stock from "overweight" down to "neutral" and slashed the target price. They brought it down from Rs 6,000 to Rs 4,000.

The reason for the downgrade seems tied to the future growth. They cut earnings estimates for the next two years by between 12 and 17 per cent. This is because they see slower growth coming, particularly in the core EMS and OSAT businesses.

JPMorgan also played with the valuation. They reduced the multiple for the core EMS business, cutting it from 45 times down to 33 times. This was based on those slower growth assumptions and those working capital worries.

Yet, the analysts aren't completely bearish. Brokerage CLSA, for instance, expected a negative market reaction given the earnings miss and the deterioration in balance sheet metrics. They called those balance sheet metrics a key monitorable.

But CLSA still held an "outperform" rating, setting a target price of ₹4,200.

The overall analyst sentiment is still a bit divided. Bloomberg data shows that twenty-four analysts are tracking Kaynes Technology right now. Fourteen of them have a "buy" rating. Six are sitting on "hold." And four have a "sell" rating. It’s a mixed bag, you know?

Investors are still trying to figure out where the company is heading. There’s a big focus on the semiconductor ambitions. Management tried to address this during the post-results call. They stressed that the OSAT facility is a huge strategic pivot. It’s supposed to move them toward a higher-margin semiconductor business.

The real pressure point, I think, is execution. Everyone is watching how they handle that Rs 2,800 crore investment plan for the OSAT facility. If they can execute successfully by 2027, it could completely change the narrative. It could shift Kaynes Tech from being just a pure-play EMS company into something more semiconductor-focused. That potential re-rating is huge.

But for now, the immediate focus is on bridging that gap. Getting the actual numbers to line up with what the company was hoping for. That’s the tightrope walk they’re on right now.